Pieris Pharmaceuticals, Inc.

Equities

PIRS

US7207952026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
10.15 ^USD	+3.70%		-3.15%	-30.29%

May. 15	Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 19	Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	MT

Pieris Pharmaceuticals, Inc. Appoints Ann Barbier to Board of Directors

April 25, 2018 at 08:00 am EDT

Pieris Pharmaceuticals, Inc. announced that Dr. Ann Barbier has joined the company's Board of Directors. Dr. Barbier is currently the Chief Medical Officer of Translate Bio. Prior to joining Translate Bio, Dr. Barbier was Vice President of Clinical Development, Rare Genetic Diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases.

Latest news about Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	Apr. 19	MT
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	Jan. 05	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Stock Futures -2-	Nov. 08	DJ
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from S&P Global BMI Index	23-09-18	CI
Vicore Pharma's New CEO to Formally Take Office	23-09-08	MT
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	23-09-01	MT
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	23-08-17	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
Pieris to Cut 70% Workforce, Hires Advisor For Strategic Review; AstraZeneca to End R&D Deal	23-07-18	MT
Pieris Pharmaceuticals to Explore Strategic Options	23-07-18	CI
Pieris Pharmaceuticals, Inc. Announces Executive Changes	23-07-13	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell Microcap Growth Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell Microcap Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index	23-06-23	CI
Sector Update: Health Care Stocks Steady to Higher Late Wednesday	23-06-21	MT
Sector Update: Health Care	23-06-21	MT

Chart Pieris Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Companyâs clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
PIERIS PHARMACEUTICALS, INC.	-30.29%	13.4M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.55%	21.96B
GENMAB A/S	-8.91%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs